AlzeCure Pharma provides a scientific update on Alzheimer's disease and the Alzstatin project platform

AlzeCure Pharma provides a scientific update on Alzheimer's disease and the Alzstatin project platform

PR Newswire

STOCKHOLM, Sept. 28, 2020

STOCKHOLM, Sept. 28, 2020 /PRNewswire/ -- AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, will hold a live business update focused on the company's Alzheimer's platform Alzstatin on Wednesday, September 30 at 10:00. The presentation will be followed by a Q&A session led by Vator Securities' analyst Felicia Rittemar.

CEO Martin Jönsson and CSO Johan Sandin will, among other things, present the pharmaceutical platform Alzstatin and the research behind it. Within the Alzstatin platform, AlzeCure develops disease-modifying and preventive drugs for Alzheimer's disease that focus on reducing the production of toxic amyloid beta (Aβ) in the brain.

Henrik Zetterberg, chief physician and professor at the Department of Neuroscience and Physiology at Sahlgrenska Academy and professor at University College of London (UCL), will participate and provide a deeper review of disease development in Alzheimer's and the amyloid hypothesis, as well as provide an update on developments in biomarkers and diagnostics in Alzheimer's.

Watch the live broadcast on September 30 from 10:00am - 11:30am CET via: https://youtu.be/3QBa97Ue75o.

The business update will be held in English and will be available on the company's website afterwards.

The information was submitted for publication, through the agency of the contact person set out above at 10:00am CET on September 28, 2020.

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is extremely limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of three symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. Alzstatin comprises two disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a clinical candidate for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase and is continuously working with business development to find suitable out-licensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.

About Alzstatin

AlzeCure's disease-modifying research platform, Alzstatin, consisting of disease-modifying and preventive drug candidates, focuses on reducing the production of toxic amyloid beta (Aβ) in the brain. Aβ plays a key pathological role in Alzheimer's and begins to accumulate in the brain years before clear symptoms develop. The drug candidates in the Alzstatin platfrom modulate the function of the enzyme gamma secretase. Gamma secretase acts like a pair of scissors and cuts Aβ42 out from a longer protein known as APP. The sticky Aβ42 clumps together giving rise to the amyloid plaque so typical of Alzheimer's disease. The candidates in the Alzstatin platform affect enzyme function so that it instead cuts out shorter forms of the Aβ peptide, Aβ37 and Aβ38, which in addition to them not being sticky and not forming aggregates, also have a restrictive effects on Aβ42 aggregates already formed. This means the drug candidates in the Alzstatin platform have two separate but synergistic effects that together contribute to a stronger anti-amyloidogenic - and thus more potent - disease-modifyning effect.

About Alzheimer's disease

Alzheimer's disease is the most common form of dementia, affecting approximately 45 million people worldwide. Alzheimer's disease is a lethal disorder that also has a large impact on both relatives and the society. Today, preventive and disease modifying treatments are missing. The main risk factors to develop Alzheimer's are age and genetic causes. Even though the disease can start as early as between 40 and 65 years of age, it is most common after 65 years. Significant investments in Alzheimer research are being made because of the significant unmet medical need and the large cost of this disease for healthcare and society. The total global costs for dementia related diseases is estimated to about 1,000 billion USD globally in 2018. Given the lack of both effective symptomatic treatments and disease modifying treatments, the need for new effective therapies is acute.The few approved drugs on the market today have only a limited symptomatic effect and can produce dose limiting side effects. A disease modifying treatment for Alzheimer's disease is estimated to reach more than 10 billion USD in annual sales. In Sweden, approximately 100,000 people suffer from Alzheimer's disease with a healthcare cost of about 63 billion SEK yearly, which is more than for cancer and cardiovascular diseases combined.

For more information, please contact
Martin Jönsson
CEO
Tel: +46-707-86-94-43
martin.jonsson@alzecurepharma.com

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

https://mb.cision.com/Main/16466/3203862/1311527.pdf

Release

https://mb.cision.com/Public/16466/3203862/b0cda065660c4e3e_org.jpeg

Martin Jönsson, VD

 

Voltar noticias em Inglês